Prof Nicholas Huntington (Monash University) is a global authority on cytokine biology and NK cell immunotherapy through which he has defined the concept of cytokine checkpoint inhibitors and supported the development of engineered cytokine biologics and CAR NK cells. He has received numerous honours (including the Australian Academy of Science Miller Medal, The Burnet Prize, NFMRI John Dixon Hughes Medal, Harry J Lloyd Trust Award, RG Menzies Award) and is embedded in global pharmaceutical strategy, serving on the Scientific Advisory Boards for Bristol Myers Squibb (BMS), Biogen & the External Advisory Board of MD Anderson’s Cell Therapy Innovation Centre and is co-founder and CSO of AUDAX Biosciences Pty Ltd.